[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,80,109,138,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":46,"locationsCount":49},"100640513","proximal-nerve-cryoablation-versus-perineuroma-cryoablation-for-chronic-neuroma-pain-after-combat-related-amputation-100640513",false,"NCT07618689","Proximal Nerve Cryoablation Versus Perineuroma Cryoablation for Chronic Neuroma Pain After Combat-Related Amputation","AXON-FREEZE","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average pain intensity ≥4\u002F10 on Numeric Rating Scale\n* Positive Tinel sign\n* Ability to undergo ultrasound-guided cryoablation\n* Stable analgesic regimen for at least 14 days\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at the treatment site\n* Open wound preventing safe procedure\n* Previous cryoablation of the target nerve within 6 months\n* Neuroma surgery within 3 months\n* Severe coagulopathy or anticoagulation contraindicating procedure\n* Pregnancy or breastfeeding\n* Severe uncontrolled systemic disease\n* Inability to complete follow-up assessments","ALL","18 Years","60 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","atients with combat-related amputations frequently develop chronic neuroma pain that interferes with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Cryoablation is a minimally invasive treatment that produces controlled nerve injury using extreme cold. Although the freezing effect is localized around the cryoprobe, axonal interruption followed by distal Wallerian degeneration may extend functional denervation distal to the ablation site.\n\nThis study aims to compare two ultrasound-guided cryoablation strategies for chronic neuroma pain after combat-related amputation: cryoablation performed directly near the neuroma and cryoablation performed proximal to the neuroma along the affected nerve.\n\nThe study will evaluate whether proximal nerve cryoablation produces greater or longer-lasting analgesic effects compared with perineuroma cryoablation.",[27,28],"Neuroma","Cryoablation",[28,30,31,32,33,34,35,36,37],"neuroma pain","combat-related amputation","phantom limb pain","residual limb pain","peripheral nerve injury","Wallerian degeneration","ultrasound-guided intervention","military trauma","NOT_YET_RECRUITING","2026-05-30",{"date":41,"type":42},"2026-06-02","ACTUAL",{"date":44,"type":21},"2026-10-15",{"date":44,"type":21},{"name":47,"class":48},"Ukrainian Society of Regional Anesthesia and Pain Therapy","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":79},"100640546","ultrasound-guided-platelet-rich-plasma-versus-local-anesthetic-injection-for-chronic-neuroma-pain-after-combat-related-amputation-100640546","NCT07624890","Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation","Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation: A Prospective Multicenter Controlled Study","PRP-NEUROMA","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average neuroma pain intensity ≥4\u002F10 on the Numeric Rating Scale\n* Persistent pain interfering with rehabilitation, prosthesis use, or daily activities\n* Ability to undergo ultrasound-guided injection\n* Stable analgesic regimen for at least 14 days before enrollment\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at or near the injection site\n* Open wound preventing safe injection\n* Previous PRP injection for neuroma pain within 6 months\n* Previous neuroma surgery within 3 months\n* Severe coagulopathy or platelet disorder\n* Anticoagulant therapy contraindicating injection\n* Active malignancy\n* Severe uncontrolled systemic disease\n* Known allergy to local anesthetics\n* Inability to complete follow-up assessments",{"count":59,"type":21},100,[24],"Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Current treatment approaches often provide only temporary pain relief.\n\nPlatelet-rich plasma (PRP) has emerged as a potential regenerative treatment option because of its possible effects on tissue healing, neuroinflammation, and peripheral nerve irritation. However, its role in the treatment of chronic neuroma pain after amputation remains unclear.\n\nThis prospective multicenter controlled study aims to compare ultrasound-guided PRP injection around the neuroma with ultrasound-guided local anesthetic injection in patients with chronic neuroma pain after combat-related amputation.\n\nParticipants will undergo one of the two injection treatments and will be followed over time to evaluate changes in pain intensity, neuropathic pain symptoms, phantom limb pain, prosthesis tolerance, and functional outcomes.\n\nThe goal of the study is to evaluate the safety, feasibility, and potential clinical effectiveness of PRP injection for chronic neuroma pain following combat-related amputation.",[27,63,64,65],"Phantom Limb Pain After Amputation","Stump Pain","Platelet-rich Plasma (PRP)",[67,68,69,70,71,72],"Chronic Neuroma Pain","Residual Limb Pain","Combat-Related Amputation","Post-Amputation Pain Syndrome","Painful Stump Neuroma","Platelet-rich plasma",{"date":74,"type":42},"2026-06-03",{"date":76,"type":21},"2026-12-15",{"date":76,"type":21},{"name":47,"class":48},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":79},"100640078","comparative-evaluation-of-intraneuroma-and-perineuroma-botulinum-toxin-type-a-injection-techniques-for-chronic-neuroma-pain-after-combat-related-amputation-100640078","NCT07624877","Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation","Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation: A Prospective Multicenter Study","IN-PERI NEUROM","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average neuroma pain intensity ≥4\u002F10 on the Numeric Rating Scale\n* Ability to undergo ultrasound-guided injection\n* Stable analgesic regimen for at least 14 days before enrollment\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at or near the injection site\n* Open wound preventing safe injection\n* Previous botulinum toxin injection for neuroma pain within 6 months\n* Previous neuroma surgery within 3 months\n* Known allergy to botulinum toxin type A\n* Coagulopathy or anticoagulation contraindicating injection\n* Severe uncontrolled systemic disease\n* Inability to complete follow-up assessments",{"count":59,"type":21},[24],"Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Ultrasound-guided botulinum toxin type A injection has emerged as a potential treatment option for persistent neuroma pain; however, the optimal injection technique remains unclear.\n\nThis prospective multicenter study aims to compare two ultrasound-guided botulinum toxin injection techniques for chronic neuroma pain after combat-related amputation: intraneuroma injection and perineuroma injection.\n\nParticipants with ultrasound-confirmed painful neuromas will undergo one of the two injection approaches based on the treating physician's clinical decision and local practice. Pain intensity, neuropathic pain characteristics, phantom limb pain, prosthesis tolerance, functional outcomes, and adverse events will be evaluated during follow-up.\n\nThe goal of the study is to evaluate the feasibility, safety, and potential clinical effectiveness of intraneuroma and perineuroma botulinum toxin type A injection techniques in patients with chronic neuroma pain following combat-related amputation.",[92,27,93,94],"Chronic Pain","Botulinium Toxin-A","Combat Trauma",[96,97,98,99,100,101,102,103],"Chronic neuroma pain","Combat-related amputation","Botulinum toxin type A","Intraneuroma injection","Perineuroma injection","Ultrasound-guided injection","Residual limb pain","Painful neuroma",{"date":74,"type":42},{"date":106,"type":21},"2026-05-27",{"date":76,"type":21},{"name":47,"class":48},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":49},"100586460","phase-2-pain-outcomes-after-digital-amputation-using-tulavi-allay-nerve-cap-100586460","NCT06915662","Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap","Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap: A Prospective Trial for Safety and Efficacy","Inclusion Criteria:\n\n* Patients undergoing traumatic amputation of a single or multiple digits at MGB\n* English-speaking\n\nExclusion Criteria:\n\n* Patients undergoing revision amputation or non-traumatic amputation\n* Patients under 22 years old\n* Patients who are pregnant and\u002For breastfeeding\n* Unable or unwilling to participate in a trial study\n* Patients with a known allergy to poly (ethylene glycol) (PEG) or the color additives FD\\&C Yellow No. 5 Dye (tartrazine) or FD\\&C Blue No. l Dye (brilliant blue FCF).","22 Years",{"count":118,"type":21},20,[120],"PHASE2","In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain. The physical and emotional burden on patients results in costs of billions of dollars annually. Digital amputations affect over 23,000 people each year in the US and may lead to neuropathic pain and neuroma formation in the transected nerves. Previous studies have reported a 6.6% incidence of symptomatic neuroma, and more than 60% of these patients require surgery to reduce the negative impact on their daily living activities.\n\nTo minimize neuroma formation after digital amputation, various techniques have been described, such as traction neurectomies (TN) and dorsal transpositions (DT), with and without nerve coaptation. However, it remains unclear whether these techniques improve patient-reported outcome measures in individuals undergoing this type of procedure. Previously published studies are descriptive in nature, focus on a single surgical technique, or include patients with established symptomatic neuromas. The only prospective trial on this topic was published in 2000 and compared two conventional techniques that have since been modified to better minimize neuroma formation or to reduce mechanical pressure by transposing the nerve ends to the dorsal aspect of the hand. However, that study used different scales to measure outcomes and did not incorporate aspects of pain that affect patients' emotional and social well-being.\n\nCurrently, two randomized controlled trials are enrolling patients. One compares surgical techniques for the treatment of neuroma rather than its prevention. The other excludes digits with injuries located distal to the interphalangeal joints. Both studies focus on more complex surgical techniques.\n\nGiven the extent of this problem, there has been recent innovation aimed at preventing neuroma formation. One promising product is the Tulavi Allay™ Nerve Cap, which has demonstrated encouraging results in basic science studies and anecdotally in early clinical use cases. In this study, the investigators have designed a prospective trial to assess the efficacy of the Tulavi Allay™ Nerve Cap when used to prevent symptomatic digital nerve neuroma following traumatic digital amputation.",[27,123],"Neuropathic Pain",[125,126,27,123,127],"Tulavi","Tulavi allay Nerve Cap","Digital Nerve Neuroma","RECRUITING","2026-04-14",{"date":131,"type":42},"2026-04-17",{"date":133,"type":42},"2025-09-20",{"date":135,"type":21},"2027-04",{"name":137,"class":48},"Massachusetts General Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":155,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":49},"100624962","neuroma-associated-pain-management-after-combat-related-trauma-in-ukraine-100624962","NCT07416448","Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine","Comprehensive Multicenter Study on the Management of Neuroma-Associated Pain Following Combat-Related Trauma in Ukraine","NAP-C\u002FR","Inclusion Criteria:\n\n* Age 18 years or older\n* Sustained combat-related trauma\n* Clinically significant neuroma-associated pain localized to a peripheral nerve or neuroma\n* Moderate to severe pain (score ≥ 4 on a standardized numeric pain rating scale)\n* Medically stable and able to undergo a percutaneous interventional procedure\n* Able to understand and provide written informed consent\n* Willing and able to comply with study procedures, including follow-up assessments and patient-reported outcome measures\n* May be receiving standard analgesic therapy, including opioids, if usage can be monitored\n* No planned surgical intervention at the neuroma site during the study period that could interfere with pain assessment\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnant or breastfeeding\n* Severe uncontrolled medical comorbidities that preclude safe participation\n* Active infection at or near the proposed intervention site\n* Known coagulopathy or use of anticoagulants that cannot be safely withheld\n* Previous cryoablation or radiofrequency ablation at the target neuroma within the past 6 months\n* Inability to provide informed consent or comply with study procedures\n* Participation in another interventional clinical trial that could interfere with study outcomes\n* Known allergy or intolerance to materials used during the procedures",{"count":20,"type":21},[24],"This multicenter interventional study in Ukraine is designed to compare the effectiveness of cryoablation and radiofrequency ablation in managing neuroma-associated pain following combat-related trauma. Adult patients with clinically significant neuropathic pain caused by neuromas will be randomly assigned to receive either image-guided cryoablation or radiofrequency ablation of the affected nerve. Cryoablation uses controlled cold temperatures to temporarily disrupt nerve conduction, while radiofrequency ablation uses thermal energy to modulate nerve function. Both interventions are minimally invasive and performed under image guidance. The study will evaluate changes in pain intensity, opioid consumption, functional outcomes, and patient-reported measures at predefined time points following the procedure. This research aims to provide evidence on which intervention is more effective in reducing pain, improving function, and minimizing the need for opioid medications in patients with combat-related neuroma pain.",[150,151,27,152,153,123,154],"Pain Management","Quality of Life","Functional Outcome","Depression in Adults","Hypoesthesia",[156,157,28,158,123],"Neuroma Pain","Combat-Related Trauma","Radiofrequency Ablation","2026-02-14",{"date":161,"type":42},"2026-02-18",{"date":163,"type":42},"2026-02-05",{"date":165,"type":21},"2027-02-05",{"name":47,"class":48},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":79},"100439891","regenerative-peripheral-nerve-interfaces-to-treat-painful-digit-and-hand-neuromas-after-amputation-100439891","NCT05008185","Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation","Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Prospective Observational Trial\"","Inclusion Criteria:\n\n* 18 years or older\n* History of unilateral digit, multiple digit, or partial hand amputation\n* Discrete neuroma pain on clinical exam\n* Following standard of care (SOC), confirmation through a local block and\u002For ultrasound imaging will be performed if indicated\n* Must be seen by a hand therapist for at least 6-week trial of desensitization therapy\n\nExclusion Criteria:\n\n* Patients with previous surgical treatment for symptomatic neuromas of the digits or hand\n* Patients with other major injuries more proximal in the ipsilateral extremity that cause chronic pain or functional loss\n* women pregnant at time of enrollment\n* prisoners\n* adults who are unable to consent",true,{"count":176,"type":21},80,"OBSERVATIONAL","This study is being done to demonstrate the effectiveness of Regenerative Peripheral Nerve Interfaces (RPNI) surgery in treating symptomatic neuromas of the hand and digits following amputation compared to standard of care using a Prospective, Observational Trial",[27],[27,156,181,182],"Finger Amputation","Hand Amputation","2024-11-26",{"date":185,"type":42},"2024-11-29",{"date":187,"type":42},"2021-10-05",{"date":189,"type":21},"2025-08",{"name":191,"class":48},"Medstar Health Research Institute"]